Greenlight Ventures Discloses Investment at Nexalin Technology with 5.6% Stake

Greenlight Ventures Discloses Investment at Nexalin Technology with 5.6% Stake

Greenlight Ventures, LLC disclosed a 5.6% stake in Nexalin Technology, Inc.'s common stock. The filing, accepted on Sep. 03, 2026, follows stock issued to Greenlight as non-cash consideration for Nexalin’s purchase of PONM. The deal also ties into a collaboration under which Greenlight provides technical and strategic support to Nexalin.

Greenlight plans to receive two remaining stock tranches tied to the $1.3 million purchase price on or about Nov. 10, 2026 and Feb. 8, 2027, with shares calculated at a set reference price and subject to anti-dilution protections. If Nexalin undergoes a change of control, “all remaining unissued Consideration Shares accelerate and become issuable immediately prior to or concurrently with” that event.

Greenlight says it may buy more or sell shares over time, but it holds no governance rights at Nexalin. The filing states, “GLV has no right…to designate or nominate any member of Nexalin’s board of directors,” and notes that director David Owens only holds a minority interest in Greenlight. A separate collaboration agreement pays Greenlight $10,000 per month for product development support and does not cover voting or share disposition.

Greenlight Ventures, LLC is a North Carolina limited liability company focused on developing and licensing software and platform technology for digital health applications. The firm partners with medical technology companies to scale software-enabled products and compliance systems. Member Peter Gratale signed the filing, and Nexalin director and Chief Medical Officer Dr. David Owens holds a minority ownership interest in the firm.

Original SEC Filing: Nexalin Technology, Inc. [ NXL ] - SCHEDULE 13D - Sep. 03, 2026